GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Current Insider Shareholdings and Options

[Updated for resignation of Greg Liposky and for small
awards of shares to independent directors in lieu of cash
payments. For GTC’s executive officers—but not the
independent directors—detailed options holdings and
exercise prices are shown in #msg-28527550.]

 
  
 Executive Officers  
 Geoffrey Cox, CEO          450K shares   991K options 
 John Green, CFO            157K shares   414K options 
 Harry Meade, SVP Research  165K shares   383K options 
 Dan Woloshen, Gen. Counsel 109K shares   287K options 
 Dick Scotland, SVP Regltry  98K shares  *267K options 
 -- 
 Five executive officers    979K shares 2,342K options

 
 Non-executive directors  
 Robert Baldridge             5K shares   105K options 
 Kenneth Bauer                 0 shares    53K options 
 Christian Béchon            40K shares    38k options 
 Francis Bullock             19K shares   188K options 
 James Geraghty             100K shares   163K options 
 Mary Ann Gray               11K shares    60K options 
 Michael Landine               0 shares    68K options 
 Pamela McNamara             13K shares    68K options 
 Marvin Miller               13K shares    68K options 
 Alan Tuck                   20K shares   118K options 
 -- 
 Ten non-executive directrs 221K shares   929K options

 
 All officers/directors   1,200K shares 3,271K options

*Estimated because Scotland’s detailed options
holdings are not reported in GTC’s SEC filings.